Glazachev OS[au] - Search Results

Year	Number of Results
1992	1
1994	2
1995	1
1996	2
1997	1
1998	1
1999	1
2001	2
2004	1
2005	1
2006	2
2007	3
2008	2
2009	1
2010	2
2012	2
2013	1
2015	1
2017	4
2018	2
2019	2
2020	3
2021	3
2022	2
2024	3

1

Kofler W, Glazachev OS, Lyshol H, Tellnes G. Kofler W, et al. Among authors: glazachev os. Scand J Public Health. 2021 Feb;49(1):9-13. doi: 10.1177/1403494820969539. Epub 2020 Nov 12. Scand J Public Health. 2021. PMID: 33176585 Free PMC article.

2

Brain-Derived neurotrophic factor and inflammatory biomarkers are unaffected by acute and chronic intermittent hypoxic-hyperoxic exposure in geriatric patients: a randomized controlled trial.

Behrendt T, Quisilima JI, Bielitzki R, Behrens M, Glazachev OS, Brigadski T, Leßmann V, Schega L. Behrendt T, et al. Among authors: glazachev os. Ann Med. 2024 Dec;56(1):2304650. doi: 10.1080/07853890.2024.2304650. Epub 2024 Jan 22. Ann Med. 2024. PMID: 38253008 Free PMC article. Clinical Trial.

3

Assessing the importance and safety of hypoxia conditioning for patients with occupational pulmonary diseases: A recent clinical perspective.

Xinliang Z, Achkasov EE, Gavrikov LK, Yuchen L, Zhang C, Dudnik EN, Rumyantseva O, Beeraka NM, Glazachev OS. Xinliang Z, et al. Among authors: glazachev os. Biomed Pharmacother. 2024 Sep;178:117275. doi: 10.1016/j.biopha.2024.117275. Epub 2024 Aug 11. Biomed Pharmacother. 2024. PMID: 39126774 Free article. Review.

4

[Pharmacological treatment of patients with chronic fatigue syndrome].

Glazachev OS, Dudnik ЕN, Zagaynaya EE. Glazachev OS, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(4):40-44. doi: 10.17116/jnevro20171174140-44. Zh Nevrol Psikhiatr Im S S Korsakova. 2017. PMID: 28617377 Clinical Trial. Russian.

5

Whole-body repeated hyperthermia increases irisin and brain-derived neurotrophic factor: A randomized controlled trial.

Glazachev OS, Zapara MA, Kryzhanovskaya SY, Dudnik EN, Yumatov EA, Susta D. Glazachev OS, et al. J Therm Biol. 2021 Oct;101:103067. doi: 10.1016/j.jtherbio.2021.103067. Epub 2021 Aug 5. J Therm Biol. 2021. PMID: 34879921 Clinical Trial.

6

Influence of acute and chronic intermittent hypoxic-hyperoxic exposure prior to aerobic exercise on cardiovascular risk factors in geriatric patients-a randomized controlled trial.

Behrendt T, Altorjay AC, Bielitzki R, Behrens M, Glazachev OS, Schega L. Behrendt T, et al. Among authors: glazachev os. Front Physiol. 2022 Oct 28;13:1043536. doi: 10.3389/fphys.2022.1043536. eCollection 2022. Front Physiol. 2022. PMID: 36388103 Free PMC article.

7

Effects of Intermittent Hypoxia-Hyperoxia Exposure Prior to Aerobic Cycling Exercise on Physical and Cognitive Performance in Geriatric Patients-A Randomized Controlled Trial.

Behrendt T, Bielitzki R, Behrens M, Glazachev OS, Schega L. Behrendt T, et al. Among authors: glazachev os. Front Physiol. 2022 May 26;13:899096. doi: 10.3389/fphys.2022.899096. eCollection 2022. Front Physiol. 2022. PMID: 35694402 Free PMC article.

8

Redox Homeostasis in Humans Exposed to Intermittent Hypoxia-Normoxia and to Intermittent Hypoxia-Hyperoxia.

Susta D, Glazachev OS, Zapara MA, Dudnik EN, Samartseva VG. Susta D, et al. Among authors: glazachev os. High Alt Med Biol. 2020 Mar;21(1):45-51. doi: 10.1089/ham.2019.0059. Epub 2020 Feb 25. High Alt Med Biol. 2020. PMID: 32096667

9

Safety and Efficacy of Intermittent Hypoxia Conditioning as a New Rehabilitation/ Secondary Prevention Strategy for Patients with Cardiovascular Diseases: A Systematic Review and Meta-analysis.

Glazachev OS, Kryzhanovskaya SY, Zapara MA, Dudnik EN, Samartseva VG, Susta D. Glazachev OS, et al. Curr Cardiol Rev. 2021;17(6):e051121193317. doi: 10.2174/1573403X17666210514005235. Curr Cardiol Rev. 2021. PMID: 33992064 Free PMC article.

10

Breast Cancer-related Lymphedema: Recent Updates on Clinical Efficacy of Therapies and Bioengineering Approaches for a Personalized Therapy.

Zhang X, Beeraka NM, Sinelnikov MY, Glazachev OS, Ternovoy KS, Lu P, Isaeva A, Cao Y, Zhang J, Nezhad AB, Plotnikova M, Chen K. Zhang X, et al. Among authors: glazachev os. Curr Pharm Des. 2024;30(1):63-70. doi: 10.2174/0113816128269545231218075040. Curr Pharm Des. 2024. PMID: 38141193

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

43 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year